KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.85

A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.

Jun Yang, Yannan Jia, Xiaoxia Hu, Fang Zhou, Xiong Ni, Jiangbo Wan, Yi Ding, Mei Kang, Xiaolin Yu, Chuanhe Jiang, Luxiang Wang, Liping Wan, Yu Cai, Chongmei Huang, Huiying Qiu, Xueying Ding, Yin Tong, Baoxia Dong, Kun Zhou, Xianmin Song

Blood 147(26) 3168-3178

PMID41849227
PMCID-
DOI10.1182/blood.2025032569
发表日期2026-03-18
入排依据:The study is a Phase III randomized trial with a time-to-event efficacy endpoint (GVHD-free, relapse-free survival). However, the intervention compares different graft-versus-host disease prophylaxis regimens (ATG, PTCy, combination) in haploidentical transplantation. The eligibility criteria require a drug-containing intervention (i.e., a drug as the primary experimental agent against a control). While ATG and cyclophosphamide are drugs, the trial's design is more procedural/regimen-focused, and the deterministic review flagged unclear drug intervention evidence. Without explicit confirmation that the trial is testing a specific drug (e.g., a new drug vs. standard) rather than comparing prophylaxis strategies, it does not meet the strict drug-intervention criterion. All other criteria are met, but the drug-intervention criterion cannot be confidently established as true, so is_eligible is false.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

The optimal graft-versus-host disease (GVHD) prophylaxis strategy in haploidentical peripheral blood stem cell transplantation remains controversial. In this open-label, phase 3 study, patients aged 14 to 70 years with acute myeloid leukemia or myelodysplastic syndromes with excess blasts Ⅰ or Ⅱ were randomized (2:1:1) to receive low-dose antithymocyte globulin (ATG; 5 mg/kg) plus posttransplant cyclophosphamide (PTCy; 50 mg/kg; referred to as ATG/PTCy), standard-dose ATG (total dose, 10 mg/kg), or a PTCy-based (total dose, 100 mg/kg) regimen for GVHD prophylaxis. The coprimary end points were the cumulative incidence (CI) of grade 2 to 4 acute GVHD (aGVHD) by day 100 and GVHD-free, relapse-free survival at 1 year after transplant. A total of 407 patients were randomized to receive an ATG/PTCy (185 patients), ATG (113 patients), or PTCy (109 patients) regimen for GVHD prophylaxis. By day +100, the CI of grade 2 to 4 aGVHD did not differ significantly among the 3 groups (P = .210). Although the overall incidence of chronic GVHD (cGVHD) was comparable across all groups (P = .110), the 2-year CI of moderate-to-severe cGVHD was numerically lower in the ATG/PTCy (17.4%) and ATG (17.3%) groups than the PTCy group (28.3%), without reaching statistical significance (P = .095). No significant differences were observed in survival outcomes among the 3 groups. Notably, the CI of neutrophil and platelet recovery was significantly higher in the ATG/PTCy group than in the other groups (P< .001). This trial suggested that the 3 GVHD prophylaxis strategies presented similar efficacy in preventing grade 2 to 4 aGVHD and yielded comparable survival. This trial was registered at www.clinicaltrials.gov as NCT03608059.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。